24/7 Wall St.9d agoneutral
Eli Lilly’s Next Trillion-Dollar Opportunity May Go Beyond Weight-Loss DrugsNotícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
104last 24h
3124last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
Investor's Business Daily38d agoneutral
Is A Cancer Vaccine Coming? Moderna, Merck Boosted By The BuzzInvestor's Business Daily39d agoneutral
After Moderna's Dizzying Rally, It's Time To Sell, Says Analyst24/7 Wall St.39d agobearish
Moderna Sinks 6% on Citi Downgrade; Merck and Pfizer Stay FlatBarrons.com39d agobearish
Moderna Stock Has Run Too Far, Too Fast. Why Citi Just Downgraded It to Sell.Investor's Business Daily40d agoneutral
AstraZeneca Digs $2 Billion Out Of Its Coffers For Summit Deal, Taking On Bristol, Pfizer, Merck24/7 Wall St.40d agoneutral
Prediction: Eli Lilly’s Next Growth Wave Could Surprise InvestorsSimply Wall St.40d agoneutral
What Does Merck (MRK) Add To Its Oncology Pipeline With This KRAS Deal?24/7 Wall St.40d agoneutral
Merck Turned $1,000 Into $3,395 in a Decade but the Real Story Happened in the Last YearBarrons.com40d agoneutral
Inside the AstraZeneca Deal That Could Send Summit Therapeutics Stock Up 162%Insider Monkey41d agoneutral
Merck (MRK) Withdrew a Cancer Filing. Is the Drug’s Promise Still Intact?